Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $5.1 million.

  • Lineage Cell Therapeutics' Share-based Compensation fell 9.85% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 3.05%. This contributed to the annual value of $5.1 million for FY2024, which is 9.42% up from last year.
  • According to the latest figures from FY2024, Lineage Cell Therapeutics' Share-based Compensation is $5.1 million, which was up 9.42% from $4.6 million recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Share-based Compensation registered a high of $5.1 million during FY2024, and its lowest value of $2.2 million during FY2020.
  • Moreover, its 3-year median value for Share-based Compensation was $4.6 million (2023), whereas its average is $4.7 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Share-based Compensation plummeted by 37.79% in 2020, and later soared by 58.02% in 2021.
  • Lineage Cell Therapeutics' Share-based Compensation (Yearly) stood at $2.2 million in 2020, then skyrocketed by 58.02% to $3.5 million in 2021, then climbed by 21.82% to $4.3 million in 2022, then rose by 8.23% to $4.6 million in 2023, then rose by 9.42% to $5.1 million in 2024.